• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-28

  Schwartz's dissertation advances the evaluation of anti-cancer drug responses by dissecting the distinct and often conflated measures of cell proliferation arrest and cell death in vitro. This nuanced approach provides researchers with more reliable tools to characterize the efficacy of apoptosis inducers and growth inhibitors, informing better translational decision-making for oncology drug discovery.

• 3D Organoid–Fibroblast Co-Cultures Reveal Chemoresistance in

  2026-05-28

  Schuth et al. developed a patient-specific three-dimensional co-culture model incorporating both pancreatic ductal adenocarcinoma (PDAC) organoids and matched cancer-associated fibroblasts (CAFs), allowing direct investigation of stromal contributions to chemoresistance. Their findings highlight the pivotal role of CAF-driven epithelial-to-mesenchymal transition (EMT) and pro-inflammatory activation in mediating reduced drug sensitivity, advancing the fidelity of preclinical drug screening for PDAC.

• Neurotensin (CAS 39379-15-2): Reliable Solutions for GPCR &

  2026-05-27

  This article provides a scenario-driven, evidence-based guide for leveraging Neurotensin (CAS 39379-15-2) (SKU B5226) in cell viability, proliferation, and cytotoxicity assays. It explores practical workflow challenges, data quality comparisons, and vendor reliability, demonstrating how APExBIO's high-purity Neurotensin enables reproducible GPCR trafficking and miRNA regulation studies.

• Deferasirox Fe3+ Chelate: Lysosomal Iron Handling in Iron Ov

  2026-05-27

  Explore how Deferasirox Fe3+ chelate advances iron overload treatment research by enabling precise investigation of lysosomal iron metabolism. This in-depth article uniquely connects chelation mechanisms to metabolic adaptation, providing new perspectives for chronic anemia and beta-thalassemia studies.

• 740 Y-P: Reliable PI 3-Kinase Activator for Cell Assay Preci

  2026-05-26

  This article delivers a scenario-driven, evidence-based exploration of 740 Y-P (SKU B5246) as a potent PI 3-kinase activator for cell viability, apoptosis, and vesicular trafficking research. Designed for biomedical researchers and technicians, it details protocol parameters, data interpretation, and product selection criteria to enhance reproducibility and experimental clarity in PI3K/AKT pathway studies.

• Caspase-3 Colorimetric Assay Kit: Applied Apoptosis Assays

  2026-05-26

  The Caspase-3 Colorimetric Assay Kit streamlines rapid, quantitative assessment of apoptosis by leveraging sensitive DEVD-pNA substrate chemistry. Its protocol flexibility and robust data output empower researchers to dissect caspase signaling in diverse models, from neurodegeneration to immune cell stress, with confidence.

• Phosphatase Inhibitor Cocktail 1: Optimizing Phosphoproteomi

  2026-05-25

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve delicate phosphorylation states across complex experimental workflows, ensuring the fidelity of phosphoproteomic and signaling analyses. From advanced Western blotting to high-throughput kinase assays, its targeted inhibition profile and robust stability deliver consistent, reproducible results across diverse applications.

• Caspase-3 Colorimetric Assay Kit: Technical Workflow Guide

  2026-05-25

  The Caspase-3 Colorimetric Assay Kit provides a streamlined solution for sensitive, quantitative detection of DEVD-dependent caspase-3 activity, supporting precise apoptosis assays and caspase activity measurement in diverse biological samples. It is best used in workflows requiring rapid, reliable apoptosis detection, but is not suitable where mechanistic or multiplexed analysis outside the caspase-3 pathway is essential.

• Bedaquiline: Mechanistic Leverage for Translational TB & Can

  2026-05-24

  This article provides translational researchers with an advanced, mechanistic perspective on Bedaquiline (a diarylquinoline antibiotic), elucidating its dual roles in multi-drug resistant tuberculosis treatment and cancer stem cell inhibition. Integrating evidence from recent host-directed therapy research, it offers actionable guidance on experimental applications, protocol parameters, and workflow optimization—while highlighting the strategic advantages of APExBIO's formulation for reproducibility and data integrity.

• Dual-Action p38α MAPK Inhibitors Promote Dephosphorylation D

  2026-05-23

  The reference study reveals that certain p38α MAPK inhibitors not only block kinase activity but also actively promote dephosphorylation of the kinase by stabilizing a conformation accessible to phosphatases. This mechanistic insight suggests a new paradigm for designing dual-action kinase inhibitors with potential for improved specificity and potency in inflammation and cancer research.

• LG 101506: RXR Modulator Applications in Cancer Signaling

  2026-05-22

  LG 101506 is redefining RXR pathway research with unmatched purity and workflow versatility. This APExBIO offering empowers scientists to dissect nuclear receptor signaling and immune evasion mechanisms, delivering reliable results in cancer and metabolism studies.

• Universal nPEC Assay for Dual-Loaded Liposome Encapsulation

  2026-05-22

  This study introduces and validates a nanoparticle exclusion chromatography (nPEC) method for accurately determining encapsulation efficiency in liposomes co-loaded with hydrophilic and lipophilic drugs. The findings establish a robust, universally applicable workflow that overcomes previous technical barriers in dual-drug liposome formulation and assessment.

• Nicotine Signaling Drives CKD Progression in Smokers

  2026-05-21

  This review dissects the mechanistic role of nicotine in accelerating chronic kidney disease (CKD) among smokers, highlighting how nicotine's activation of non-neuronal acetylcholine receptors and downstream oxidative and fibrotic pathways contribute to renal injury. The findings stress the importance of targeting nicotine-mediated mechanisms in CKD management and research.

• CKI 7 Dihydrochloride: Precision Casein Kinase 1 Inhibitor W

  2026-05-21

  CKI 7 dihydrochloride empowers researchers to unravel Casein kinase 1 pathways with exceptional selectivity, supporting breakthrough studies in signal transduction, circadian biology, and cancer metastasis. Robust protocol guidance and troubleshooting tips ensure reproducibility and maximize assay impact.

• DNase I (RNase-free): Advanced Chromatin Digestion & RNA Pre

  2026-05-20

  Discover how ribonuclease-free DNase I enables precise chromatin digestion and DNA removal for high-purity RNA workflows. Explore unique protocol insights, advanced mechanisms, and the biochemical innovations underpinning this essential APExBIO enzyme.

16172 records 1/1079 page Next 12345 下5页 Last page